Proteome Sciences declared on Monday that it has secured a third contract from a US biopharmaceutical client to develop a new mass-spectrometry-based assay at its Frankfurt facility ahead of the customer's planned clinical trial programme in 2026.

The GCLP-compliant initial phase will support assay development for use in a trial scheduled to begin at the end of Q1 2026. Follow-on phases are expected to mirror the scope of contracts awarded in February 2025. A portion of the work will be recognised in the current financial year, with the remainder completing by the end of Q1 2026.

Proteome Sciences provides contract proteomics services for drug discovery, development and biomarker identification, including SysQuant, TMTMS2, Super-Depletion and TMTcalibrator, alongside targeted mass-spectrometry assay development.